Abstract 2108
Background
RANGE previously reported positive progression-free survival1 and a trend towards improved overall survival (OS)2 in ramucirumab (RAM) treated patients. Exploratory biomarker analysis of efficacy by programmed death-ligand 1 (PD-L1) expression revealed a hazard ratio (HR) for OS of 0.519, p = 0.0048 in patients with a PD-L1 combined positive score (CPS)≥10 compared to HR of 0.999, p = 0.9955 in patients with a PD-L1 CPS<10. We aim to understand prognostic and predictive factors related to survival outcomes in RANGE, and to identify patients who may benefit from RAM therapy using PD-L1 immunohistochemistry and gene expression analysis, defining molecular subtypes, and tumour microenvironment signatures.
Methods
Archival tumour specimens that met assay stability requirements (238/530 ITT patients in RANGE) were analyzed with the 22C3 PD-L1 antibody with CPS based on tumour cell (TC) and immune cell (IC) staining. RNA expression analysis on archival tumour tissue (394/530 ITT patients) was done by GenomeDx (RNA microarray)3. PD-L1 groups, urothelial carcinoma molecular subtypes, and immune4 and stromal phenotypes5 were determined and analyzed for association with OS outcome.
Results
Overall, RAM had the greatest improvement in OS in patients with TC ≥ 1, IC ≥ 4 or CPS≥10 PD-L1 status. OS was also more improved in patients with basal subtypes, with considerable overlap noted between basal subtypes and TC ≥ 1, IC ≥ 4, or CPS ≥10 PD-L1 status. In the subgroup with both basal/basal claudin-low subtype and CPS≥10 PD-L1 status, median OS was 9.2 months with RAM and 6.0 months with placebo (stratified hazard ratio 0.47; 95% confidence interval: 0.27-0.84, p = 0.01, n = 79).
Conclusions
Our analysis suggested significant improvement in OS in RAM treated patients with platinum refractory urothelial carcinoma, and with both basal subtype and positive PD-L1 status. References: 1Petrylak et al, Lancet 2017; 390:2266-77; 2Petrylak et al, Ann Oncol 2018; 29:viii304-5; 3Seiler et al, Eur Urol 2017; 72:544-54; 4Charoentong et al, Cell Rep 2017; 18:248-62; 5Uhlik et al Cancer Res 2016; 76:2573-86.
Clinical trial identification
NCT02426125.
Editorial acknowledgement
Lisa Cossens and Antonia Baldo of Syneos Health, funded by Eli Lilly and Company.
Legal entity responsible for the study
Eli Lilly and Company.
Funding
Eli Lilly and Company.
Disclosure
T.B. Powles: Research grant / Funding (self), Personal fees: Roche; Research grant / Funding (self), Personal fees: AZ; Licensing / Royalties, Personal fees: Merck; Licensing / Royalties, Personal fees: Eli Lilly and Company; Licensing / Royalties, Personal fees: BMS; Licensing / Royalties, Personal fees: Pfizer. D.P. Petrylak: Research grant / Funding (self): Eli Lilly and Company; Licensing / Royalties, Personal fees: Bayer; Research grant / Funding (self), Licensing / Royalties, Personal fees: Bellicum; Research grant / Funding (self), Licensing / Royalties, Personal fees: Dendreon; Research grant / Funding (self), Licensing / Royalties, Personal fees: Sanofi Aventis; Research grant / Funding (self), Licensing / Royalties, Personal fees: Johnson and Johnson; Licensing / Royalties, Personal fees: Exelixis; Licensing / Royalties, Personal fees: Ferring; Research grant / Funding (self), Licensing / Royalties, Personal fees: Millineum; Licensing / Royalties, Personal fees: Medivation; Licensing / Royalties, Personal fees: Pfizer; Research grant / Funding (self), Licensing / Royalties, Personal fees: Roche Laboratories; Research grant / Funding (self), Licensing / Royalties, Personal fees: Tyme Pharmaceuticals; Research grant / Funding (self): Oncogenix; Research grant / Funding (self): Progenics; Research grant / Funding (self): Merck; Research grant / Funding (self): Agensys. R. de Wit: Licensing / Royalties: Eli Lilly and Company; Licensing / Royalties: Merck; Licensing / Royalties: Roche; Licensing / Royalties: Sanofi. K.N. Chi: Research grant / Funding (institution): Eli Lilly and Company. A. Necchi: Research grant / Funding (self), Licensing / Royalties, Non-remunerated activity/ies: Roche; Licensing / Royalties: Merck; Licensing / Royalties: AstraZeneca; Licensing / Royalties: Seattle Genetics; Licensing / Royalties: Bayer. C.N. Sternberg: Licensing / Royalties: Eli Lilly and Company; Licensing / Royalties: BMS; Licensing / Royalties: Merck/Pfizer; Licensing / Royalties: Clovis. S.A. Hussain: Research grant / Funding (institution): Janssen; Research grant / Funding (institution): Seattle Genetics; Research grant / Funding (institution): MSD; Research grant / Funding (institution): BMS. A. Bamias: Licensing / Royalties: AstraZeneca; Licensing / Royalties: BMS; Research grant / Funding (self), Licensing / Royalties: Roche. M.S. Xia: Shareholder / Stockholder / Stock options, Full / Part-time employment: Eli Lilly and Company. E. Rasmussen: Shareholder / Stockholder / Stock options, Full / Part-time employment: Eli Lilly and Company.A. Aggarwal: Shareholder / Stockholder / Stock options, Full / Part-time employment: Eli Lilly and Company. S.R. Wijayawardana: Shareholder / Stockholder / Stock options, Full / Part-time employment: Eli Lilly and Company. K. Bell-McGuinn: Shareholder / Stockholder / Stock options, Full / Part-time employment: Eli Lilly and Company. All other authors have declared no conflicts of interest.
Resources from the same session
5517 - Molecular fingerprinting in breast cancer (BC) screening using Quantum Optics (QO) technology combined with an artificial intelligence (AI) approach applying the concept of “molecular profiles at n variables (MPnV)”: a prospective pilot study.
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 3
Resources:
Abstract
2152 - Inferring the correlation between incidence rates of melanoma and the average tumor-specific epitope binding ability of HLA class I molecules in different populations
Presenter: Istvan Miklos
Session: Poster Display session 3
Resources:
Abstract
4382 - Thermal Liquid Biopsy as a Valuable Tool in Lung Cancer Screening Programs
Presenter: Alberto Rodrigo
Session: Poster Display session 3
Resources:
Abstract
2465 - Towards a screening test for cancer by circulating DNA analysis
Presenter: Rita Tanos
Session: Poster Display session 3
Resources:
Abstract
3788 - Evaluation of a successful launch of the MammaPrint and BluePrint NGS kit
Presenter: Leonie Delahaye
Session: Poster Display session 3
Resources:
Abstract
3863 - Analysis of prognostic factors on overall survival in elderly women treated for early breast cancer using data mining and machine learning
Presenter: Pierre Heudel
Session: Poster Display session 3
Resources:
Abstract
1993 - Circulating tumor cell detection in epithelial ovarian cancer using dual-component antibodies targeting EpCAM and FRα
Presenter: Na Li
Session: Poster Display session 3
Resources:
Abstract
4281 - CEUS of the breast: Is it feasible in improved performance of BI-RADS evaluation of critical breast lesions?——A multi-center prospective study in China
Presenter: Jun Luo
Session: Poster Display session 3
Resources:
Abstract
2268 - Classification of abnormal findings on ring-type dedicated breast PET for detecting breast cancer
Presenter: Shinsuke Sasada
Session: Poster Display session 3
Resources:
Abstract
4035 - Prediction of benign and malignant breast masses using digital mammograms texture features
Presenter: Cui Yanhua
Session: Poster Display session 3
Resources:
Abstract